Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.

This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.

References



Natalizumab als Spritze 1000 Gesichter

EMAZulassung Natalizumab subcutan MS Gesellschaft NÖ

Zercepac Neues Trastuzumab Biosimilar APOTHEKE ADHOC

Atezolizumab plus Bevacizumab bei HCC?

Erster biosimilarer Antikörper für die HämatoOnkologie Management